Skip to page body Patient Care Survivorship Research Cancer Types News Giving Community Partners Clinical Trials
UCLA's Jonsson Comprehensive Cancer Center
Take the Jonsson Cancer Center Site Survey

JCCC Member Directory

Allan Pantuck, M.D., M.S., F.A.C.S.
Allan Pantuck, M.D., M.S., F.A.C.S.

Specialty:

Urology

General Information:

Gender:
Male
Language(s):
English

Affiliation(s):

Associate Professor, Department of Urology
Director of Translational Research, UCLA Kidney Cancer Program
Co-Director, Integrative Urology Program
Member, JCCC Tumor Immunology Program Area

Hospital Affiliation(s):

Ronald Reagan UCLA Medical Center

Education:

Fellowship:
Urology / Oncology, UCLA School of Medicine, 1999 - 2002
Residency:
Urology, Robert Wood Johnson University Hospital, Pediatrics, 1995 - 1999
Internship:
Surgery, Robert Wood Johnson University Hospital, Pediatrics, 1993 - 1995
Medical Degree:
M.D., Robert Wood Johnson Medical School, 1993

Certification(s):

Medical Board Certification(s):
Urology, American Board of Urology, 2004

Contact Information:

Urology:
(310) 794-7700 Information and referral
(310) 825-5088 Department office
Phone:
(310) 206-2436
Email:

Practice Information:

Clinical Interest(s):
Bladder Cancer
Cryosurgery
Gene Therapy
General Urology, Male
Hematuria
Kidney Cancer
Laser
Microwave Therapy For BPH
Nerve Sparing Prostatectomy
Oncology
Penile Cancer
Prostate Cancer
Prostate General
Prostate Nodules
Testicular Cancer
Urinary Diversion

Scientific Interest(s):

Dr. Allan Pantuck's research focuses on the molecular and genetic determinants underlying response to immunotherapy in patients with kidney cancer, as well as the nutritional aspects of bladder and prostate cancer prevention and treatment.

Selected Cancer-Related Publications:

Atkins MB, Ernstoff MS, Figlin RA, Flaherty KT, George DJ, Kaelin WG, Kwon ED, Libermann TA, Linehan WM, McDermott DF, Ochoa AC, Pantuck AJ, Rini BI, Rosen MA, Sosman JA, Sukhatme VP, Vieweg JW, Wood CG, King L. Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res. 2007; 13(2 Pt 2): 667s-670s.

Klatte T, Pantuck AJ. Editorial Comment on:"A Review on Follow-Up Strategies for Renal Cell Carcinoma after Nephrectomy" Eur Urol. 2007.

Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. Protein expression profiles in renal cell carcinoma: staging, prognosis, and patient selection for clinical trials. Clin Cancer Res. 2007; 13(2 Pt 2): 703s-708s.

Hung RJ, Zhang ZF, Rao JY, Pantuck A, Reuter VE, Heber D, Lu QY. Protective effects of plasma carotenoids on the risk of bladder cancer. J Urol. 2006; 176(3): 1192-7.

Jin Y, Iwata KK, Belldegrun A, Figlin R, Pantuck A, Zhang ZF, Lieberman R, Rao J. Effect of an epidermal growth factor receptor tyrosine kinase inhibitor on actin remodeling in an in vitro bladder cancer carcinogenesis model. Mol Cancer Ther. 2006; 5(7): 1754-63.